Stability, Permeability and Growth-Inhibitory Properties of Gonadotropin-Releasing Hormone Liposaccharides

[1]  I. Toth,et al.  Synthesis and in vitro evaluation of glycosyl derivatives of luteinizing hormone-releasing hormone (LHRH). , 2013, Bioorganic & medicinal chemistry.

[2]  I. Toth,et al.  Lipidated analogues of luteinizing hormone-releasing hormone (LHRH) reduce serum levels of follicle-stimulating hormone (FSH) after oral administration. , 2012, International journal of pharmaceutics.

[3]  M. Scarino,et al.  A protocol for in situ enzyme assays to assess the differentiation of human intestinal Caco-2 cells. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[4]  Qiong-yan Lin,et al.  Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice , 2012, Journal of Zhejiang University SCIENCE B.

[5]  I. Toth,et al.  Peptides as therapeutics with enhanced bioactivity. , 2012, Current medicinal chemistry.

[6]  I. Toth,et al.  Modern Lipid-, Carbohydrate-, and Peptide-Based Delivery Systems for Peptide, Vaccine, and Gene Products , 2011 .

[7]  J. Pinski,et al.  Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer , 2011, Expert opinion on investigational drugs.

[8]  R. Bass,et al.  N-terminal Glutamate to Pyroglutamate Conversion in Vivo for Human IgG2 Antibodies , 2011, The Journal of Biological Chemistry.

[9]  J. Kvetina,et al.  Caco-2 cells, biopharmaceutics classification system (BCS) and biowaiver. , 2011, Acta medica.

[10]  R. Rink,et al.  To protect peptide pharmaceuticals against peptidases. , 2010, Journal of pharmacological and toxicological methods.

[11]  G. Mező,et al.  Receptor-mediated tumor targeting based on peptide hormones , 2010, Expert opinion on drug delivery.

[12]  S. Ferracuti,et al.  GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors , 2009, Endocrine.

[13]  D. Harrison,et al.  Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. , 2008, Cancer research.

[14]  M. D. Del Borgo,et al.  Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. , 2008, Bioorganic & medicinal chemistry.

[15]  M. Tesone,et al.  Regulation of ovarian angiogenesis and apoptosis by GnRH‐I analogs , 2008, Molecular reproduction and development.

[16]  P. Leung,et al.  Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion , 2007, Endocrine.

[17]  A. Schally,et al.  Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[18]  A. Vizel’,et al.  Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development. , 2006, Journal of pharmaceutical and biomedical analysis.

[19]  D. Craik,et al.  The synthesis and structure of an n-terminal dodecanoic acid conjugate of α-conotoxin MII , 2006, Letters in Peptide Science.

[20]  A. Schally,et al.  Minireview. Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers1 , 2005, Biology of reproduction.

[21]  A. H. Wang,et al.  Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  I. Toth,et al.  The stability of lipidic analogues of GnRH in plasma and kidney preparations: the stereoselective release of the parent peptide. , 2005, Bioorganic & medicinal chemistry letters.

[23]  P. Travers,et al.  Expression of gonadotropin-releasing hormone type-I (GnRH-I) and type-II (GnRH-II) in human peripheral blood mononuclear cells (PMBCs) and regulation of B-lymphoblastoid cell proliferation by GnRH-I and GnRH-II. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[24]  C. Leuschner,et al.  Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors , 2003, The Prostate.

[25]  M. Motta,et al.  Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. , 2003, Endocrine-related cancer.

[26]  R. Millar,et al.  Conformational constraint of mammalian, chicken, and salmon GnRHs, but not GnRH II, enhances binding at mammalian and nonmammalian receptors: evidence for preconfiguration of GnRH II. , 2002, Molecular endocrinology.

[27]  A. Wells,et al.  Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  G. Emons,et al.  Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. , 2002, The Journal of clinical endocrinology and metabolism.

[29]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[30]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[31]  N. Auersperg,et al.  Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. , 2001, Endocrinology.

[32]  M. Brawer.  The evolution of hormonal therapy for prostatic carcinoma. , 2001, Reviews in urology.

[33]  G. Emons,et al.  Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. , 2000, Gynecologic oncology.

[34]  L. Frati,et al.  Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP. , 2000, Journal of andrology.

[35]  P. Leung,et al.  Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. , 2000, Endocrinology.

[36]  D. Kim,et al.  Antitumor effect of GnRH agonist in epithelial ovarian cancer. , 1999, Gynecologic oncology.

[37]  Shuk-Mei Ho,et al.  Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells , 1999 .

[38]  P. Leung,et al.  Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. , 1999, The Journal of clinical endocrinology and metabolism.

[39]  S. Mok,et al.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Starr,et al.  Synthesis and in vitro evaluation of lipoamino acid and carbohydrate-modified enkephalins as potential antinociceptive agents , 1998 .

[41]  P. Artursson,et al.  Oral absorption studies of lipid-polylysine conjugates of thyrotropin releasing hormone (TRH1) and luteinizing hormone releasing hormone (LHRH1) , 1996 .

[42]  S. Kakar,et al.  Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues. , 1995, Cancer letters.

[43]  M. Motta,et al.  Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. , 1994, Cancer research.

[44]  P. Artursson,et al.  Lipidic conjugates of luteinizing hormone releasing hormone (LHRH)+ and thyrotropin releasing hormone (TRH)+ that release and protect the native hormones in homogenates of human intestinal epithelial (Caco-2) cells , 1994 .

[45]  I. Toth.  A novel chemical approach to drug delivery: lipidic amino acid conjugates. , 1994, Journal of drug targeting.

[46]  A. Schally,et al.  High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. , 1993, Cancer research.

[47]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[48]  I. Toth,et al.  Lipidic Peptides. Part 1. Synthesis, Resolution and Structural Elucidation of Lipidic Amino Acids and Their Homo- and Hetero- Oligomers. , 1991 .

[49]  I. Toth,et al.  Lipidic peptides, I. Synthesis, resolution and structural elucidation of lipidic amino acids and their homo- and hetero-oligomers , 1990 .

[50]  K. Eidne,et al.  Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. , 1987, The Journal of clinical endocrinology and metabolism.

[51]  Y. Shimonishi,et al.  A new method for releasing oxytocin from fully-protected nona-peptides using anhydrous hydrogen fluoride. , 1965, Bulletin of the Chemical Society of Japan.